IL7 signaling is critical for lymphopoiesis and, in the context of T-ALL, it plays a role in activation of the JAK/STAT5 and PI3K/Akt/mTOR pathways, with 10% of patient leukemia samples containing activating IL7r mutations (184–186). Here, MTOR is linked to acute lymphoblastic leukemia.